Inspire Medical Systems, Inc.
INSP · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.29 | 5.12 | -40.44 | 5.03 |
| FCF Yield | 1.65% | 0.02% | 0.03% | -0.40% |
| EV / EBITDA | 83.03 | -339.99 | -162.96 | -157.72 |
| Quality | ||||
| ROIC | 4.58% | -6.73% | -9.42% | -15.14% |
| Gross Margin | 84.68% | 84.54% | 83.79% | 85.74% |
| Cash Conversion Ratio | 2.43 | -1.17 | -0.26 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 25.32% | 38.85% | 52.33% | 6,156,816.01% |
| Free Cash Flow Growth | 8,798.73% | -58.59% | 109.98% | 55.34% |
| Safety | ||||
| Net Debt / EBITDA | -1.82 | 9.42 | 10.62 | 4.67 |
| Interest Coverage | 1,640.14 | 0.00 | -28.38 | -18.73 |
| Efficiency | ||||
| Inventory Turnover | 1.54 | 2.85 | 5.56 | 1.93 |
| Cash Conversion Cycle | 165.27 | 33.79 | -27.80 | 114.50 |